2 employees
Metys Pharmaceuticals is developing MP-101 to prevent and treat chemotherapy-induced peripheral neuropathy.
2013
$82K
from 1 investors over 1 rounds
Metys Pharmaceuticals raised $82K on January 1, 2019
Investors: Executive Agency for Small and Medium-sized Enterprises (EASME)